Fundraising Fox
/Companies
Sign in

LENZ Therapeutics, Inc.

NASDAQ: LENZ

South San Francisco, US · Founded 2019 · 2 known investors

Find your way into LENZ Therapeutics, Inc.

Sign up to see every warm intro you have to LENZ Therapeutics, Inc.

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the LENZ Therapeutics, Inc. team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision.

Biotech

Founders & leadership

JL
Josh LehrerExecutive
KSKatherine Stultz
Katherine StultzExecutiveKatherine Stultz is an executive leader with experience in biotech company leadership, clinical development, and commercialization across multiple organizations and board roles.
PG
Philip GutryExecutive
ES
Evert SchimmelpenninkChief Executive Officer, President, Secretary, and Director
DC
Daniel ChevallardChief Financial Officer
SOShawn Olsson
Shawn OlssonChief Commercial Officer
MO
Marc OdrichChief Medical Officer

Board

AB
Abraham BassanBoard director
JDJerel Davis
Jerel DavisBoard directorManaging Director at Versant Ventures
CRCarlo Rizzuto
Carlo RizzutoBoard directorManaging Director at Versant Ventures
PK
Perry KarsenBoard director
JJ
Joe JimenezBoard director

Investors · 2

Versant VenturesreportedSan Francisco · $250K – $5M

How we know: the S-1 prospectus · a partner's Signal profile · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$150.7M disclosed across 1 round · 2021

▶$150.7MraisedMar 2021 · 35 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Perry KarsenDirector
  • Abraham BassanDirector
  • Josh LehrerExecutive Officer, Director
  • Katherine StultzExecutive Officer
  • Philip GutryExecutive Officer
  • Jerel DavisDirector
  • Joe JimenezDirector
  • Matthew PorteusDirector
  • Carlo RizzutoDirector
  • Maria Grazia RoncaroloDirector
Offering amount
$150.7M
Amount sold
$150.7M
First sale
Mar 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$951.6Mvaluation at IPOJun 2021 · $17.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Frequently asked questions

What does LENZ Therapeutics, Inc. do?
Late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision.
Who are LENZ Therapeutics, Inc.'s investors?
LENZ Therapeutics, Inc.'s investors include Samsara BioCapital, Versant Ventures.
How much funding has LENZ Therapeutics, Inc. raised?
LENZ Therapeutics, Inc. has disclosed $150.7M raised across 1 round.
Where is LENZ Therapeutics, Inc. headquartered?
LENZ Therapeutics, Inc. is headquartered in South San Francisco, US.